Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan in patients with nonalcoholic fatty liver disease
IRCT20180412039283N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of losartan in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: blood pressure, fasting blood sugar and 2 more. Started Jan 2019; status: completed.
02
Drugs
losartan
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20180412039283N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180412039283N1.